Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. Over the next few years, immuno-oncology ...

Q1 2025 Management View CEO Leonard Schleifer highlighted mixed performance in Q1 2025, with challenges in the retinal ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell ...

Regeneron’s net income in Q4 was $918 million. As typical for Regeneron, it did not provide revenue guidance. As of December 31, Regeneron held $2.488 billion in cash and cash equivalents.

Regeneron Pharmaceuticals, Inc. announced that it will present new and updated data from its oncology and hematology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. Over the next few years, immuno ...

Compared to Q4 2024, Q1 2025 saw a decline in EYLEA net ... pressures and potential delays in key product approvals. Regeneron faced mixed results in Q1 2025 with challenges in its retinal ...